US Pharma MarketingEU regulators recommend revoking the marketing authorization for Amgen’s Tavneos
EMA Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
The European Medicines Agency has proposed revoking the marketing authorization for Amgen’s controversial rare disease drug Tavneos citing “incorrect and misleading” clinical data.
The future of Amgen’s Tavneos has been in turmoil after being linked ...
Source: Endpoints News